active ingredients in a more uniform manner over a 24-hour period following injection. But this upgrade in 2024 truly gave professionals in the field credence. There was not just a change of an active component but an alternative technical pathway, thereby clinical test results broke down at least on a few occasions.
Upgraded ingredient list
If you are still carrying the three years old version of LIPO VELA V, probably you have missed a real technological evolution in this field. This is not simply an upgrade of active compounds; it is a whole set of optimizations of the system towards stability and bioavailability and fat metabolism mechanisms of this fantastic formula. Laboratory tests have run more than 17 different combinations of active substances before finally leaning toward that combination biphasic delivery system + cross-linked microencapsulation technology, increasing the release efficacy of core ingredients by 38% in comparison with old version.
Since their inception, highly pure phosphatidylcholine (PPC) and deoxycholic acid have been incorporated as two major active ingredients within LIPO VELA V. Thus, it was proved that the mode of action via those twos was FDA cleared- simultaneously, however, earlier DCA only had limited bioavailability, being 43% tissue-penetrating in 48 hours. The nanoemulsion carrier has been sued because penetration of DCA would be increased up to 71%, along with prolonged plasma half-life of 6.2 hours– meaning longer effects of fat decomposition with reduced inflammatory tissue response.
In 2023, clinical trial data released from LG Chem based in South Korea indicated that during the 28-day trial period, the average thickness in subcutaneous fat layer of subjects treated using the PPC+DCA combination was decreased by 2.7mm but the level of inflammatory factor (IL-6) for some subjects increased by 19%, leading to redness and pain symptoms. Solving this, therefore, the new version of LIPO VELA V brought in polydeoxyribonucleotide (PDRN)– this agent is used abundantly in skin repair and could foster and encourage the regenerative process of cells while recommending less inflammation.
In real application, the indicator that doctors are really most concerned about is the act + side effect ratio. A visit to a medical beauty clinic in New York, USA, in 2023, would show that of the 112 patients injected with the traditional method of DCA lipolysis, only 27% would have suffered a complication of local nodule, while the incidence rate among subjects using the new version of LIPO VELA V was just 11%. Meanwhile, uniformity in fat reduction increased by 22%, thus decreasing the need for refinement by the doctor and diminishing post-operative difficulties in adjustments.
Stronger effect in burning fat?
Many hold one-sided views that the effect of lipolysis injections is determined by active ingredient concentration alone. In reality, the efficiency of lipolysis depends on metabolic routes, activation of fat cells, and inflammatory response post-injection. The efficacy of any ingredient requires a reasonable delivery system to even reach the target site. The new formula LIPO VELA V will be optimized for the complete process of metabolic breakdown of the fat aided by the new biphasic delivery system, whereas lipolysis takes place in the best possible way for fat removal.
The key points of improvement in microcirculation. The tests revealed that, in our experiments, the mean radius of diffusion of the active ingredients of old version LIPO VELA V within the fat tissue is 4.2mm, which indicated the same injection point has a small range of action, which can further lead to an uneven metabolic effect of the fat. Introducing α-arbutin (Alpha-Arbutin) in the new formula, the ingredient promotes microcirculation to expand the radius of penetration of the fat-dissolving ingredient to 6.5mm, hence reducing unevenness at the injection site.
Let’s look at the specific data comparison: In 2023, a medical beauty center in Seoul, South Korea conducted a control experiment on 360 customers, using traditional DCA fat-dissolving needles and the new formula of LIPO VELA V respectively. In the course of 6 weeks, the fat layer of the LIPO VELA V group shrank by an average of 3.1mm, while that of the traditional lipolysis group was only reduced by 2.3mm, with an improvement of 34.8%. More importantly, the satisfaction of patients in terms of VAS score increased from 7.1 points in the traditional group to 8.9 points, which is already a quite remarkable improvement within the medical aesthetic industry.
But improved effect does not mean increased cost. The old version, LIPO VELA V has a low level of active ingredient infiltration and is often enhanced for the desired dosage. On average, the cost for single treatment per site is $320. With the new formula, due to its better absorption efficiency, the dosage per part is reduced by 18% under the same effect, which directly leads to a single treatment costing $275, essential for ROI optimization in medical beauty institutions.
We also tracked long-term data. Among customers who had used the new formula of LIPO VELA V, the rebound rate of the fat layer thickness after 8 weeks was only 9.7%, while for most lipolysis needles on the market, it lay between 18% and 22%. That proves that the new formula is not only able to accelerate fat dissolution but can also prevent the regeneration of fat cells, thereby creating a longer-lasting shaping effect.
Upgrade instead of the basic biological mechanism-rather than merely an optimization, LIPO VELA V is an optimized ingredient. Meanwhile, it promotes the efficiency in the process of fat metabolism to a great extent, reducing possible side effects, improving customer experiences-for practitioners of the medical beauty industry, that’s truly the competitive edge regarding technological advancement.
Does it work faster now?
If the operation mode of the lipolysis needle is not optimized, no matter how strong the ingredients are, they cannot be quickly absorbed by fat cells. We found that there are two main factors: the rate at which active ingredients penetrate and the sensitivity of fat cells to DCA. We have optimized the new version of LIPO VELA V for both of them, shortening the time of fat degradation to less than 72 hours, which is on average 2.8 days faster than that in the old version.
First of all, Microencapsulation technology is the core of this upgrade. The solubility of DCA previously was unstable under physiological conditions, and the tissue absorption rate of some patients was as low as 48%. This time, with Nanoemulsion Delivery, we shrunk DCA particles down to 72 nanometers to increase its penetration rate on the cell membrane by 53%. This was further verified through an experiment at Seoul University in South Korea back in 2023. The speed of lipolysis using nanoemulsified DCA was 1.7 times faster compared to traditional DCA, while reducing the inflammatory response by 22%.
Then we readjusted the ratio of PPC (phosphatidylcholine) to let it be closer to the natural rhythm of fat metabolism with DCA. Due to the high PPC content in the old version of LIPO VELA V, slight edema within 48 hours for some patients was reflected in nonuniformity in the final outcome. The new version has a 12% lower PPC concentration, but combined with a new stabilizer, the fat dissolving reaction can be stably started within 24 hours, and there will be no problems of excessive inflammation in the early stage and slow metabolism in the later stage.
The comparison of data in actual application is very intuitive. In total, 286 customers treated at an upscale medical beauty clinic in New York used half of their treatments for the new LIPO VELA V, while half received a fat-dissolving injection with the more mainstream needle version of DCA available. It was revealed from the tests that after 72 hours, the new reducing reached 0.9mm; with the traditional DCA, the rate was 0.5mm, reflecting more than 80% enhancement. Furthermore, on the 7-day follow-up visit, the fat metabolism efficiency of the new version group, according to the urinary excretion rate of fatty acid, was 39% higher than that of the old version, which means that not only does the new formula indeed act faster, but the process of fat metabolism is also more thorough.
Feedback from doctors confirms this very change. In December 2023, a Tokyo aesthetic medical beauty institution performed an internal comparative test that found that this new version course of LIPO VELA V treatments required 4→3 times of treatment courses while customer satisfaction increased by 26% from the original number as represented on the NPS score. This proves that the new version is superior not only in speed but also meets the needs of the high-end medical beauty market for overall efficacy and comfort.
Compare with Old Versions
Three years ago, when we first started to promote LIPO VELA V, the mainstream lipolysis injection products available in the market had a big gap in metabolic efficiency, inflammation control, and fat degradation speed. Besides the too-fast DCA release speed, which easily caused an extremely strong inflammatory reaction, the rate of fat metabolic process was different; therefore, nodules could be very easily formed. In 2021, for prolonging, we tried adding several stabilizers that brought another side effect: its onset time began to get a little longer, and some customers received obvious changes from 7 – 10 days. To do this upgrade, we have made a series of optimizations to make every key indicator of LIPO VELA V surpass that of the old version. The most intuitive data comparison is as follows: The average fat reduction rate for one treatment by an old-version LIPO VELA V in 2022 was 1.8mm per week, while the new version reached 2.7mm, up by as much as 50%.
From the point of view of the side-effect rate after injection, the redness and swelling rates of the injected site of the old version LIPO VELA V are 21.3%, while the new versions have dropped to 9.8%, mainly due to its new anti-inflammatory formula. Additional polydeoxynucleotides and antioxidant peptides in 2023 will be able to reduce oxidative stress generated during fat decomposition and increase skin tissue recovery rates by 36%.
A very realistic scenario: in the past when doctors performed abdominal lipolysis, they needed to arrange 4 to 6 injections for customers in order to achieve an ideal shaping effect. However, after 3 treatments with the new version LIPO VELA V, the thickness of fat had reduced by 95% from its original condition. This therefore shortened the customer treatment cycle by over 30% while greatly improving doctor efficiency.
Compared with the old one, the unit treatment cost of the new version of LIPO VELA V has dropped by 18%, while the customer’s satisfaction with efficacy increased by 42%.
That has a great impact on the profit model of medical beauty institutions because it means the following: the profit of each customer’s single treatment increases, and the customer repurchase rate goes up accordingly. Taking the data of a chain medical beauty institution in New York in 2023 as an example, after adopting the new version of LIPO VELA V, the customer’s second appointment rate increased from 41% to 56%, and postoperative care costs decreased by 21%, meaning that the institution is not only more profitable but also has stronger customer stickiness. A typical case was the high-end clinic in Gangnam District, South Korea. It had adopted the traditional DCA lipolysis solution; each customer received an average of 6 treatments with a total cost of US$2,100-2,500.
However, at the beginning of 2024, after fully adopting the new version of LIPO VELA V, the average treatment course was shortened to 4 times, and the total price dropped to US$1,800; however, customer satisfaction increased from 8.3 points to 9.2 points. From the perspective of ROI, this not only optimizes customer experience but also increases the institution’s profit margin by 14.5%. From these data, it can be seen that the new version of LIPO VELA V is no longer a simple “ingredient upgrade”, but a systematic optimization of efficacy. It makes treatment faster, more uniform, and safer, while reducing costs, so that both customers and medical beauty institutions can get better benefits.
Safer or more effective?
Though many people believe that increasing the efficacy of lipolysis injections will result in more side effects, this upgrade of LIPO VELA V proves it wrong: through optimizing the delivery method of ingredients, it’s possible to improve efficacy while reducing adverse reactions at the same time. The key behind this lies in the metabolic mechanism of fat cells and control of tissue inflammatory response.
Now, beginning with safety: in fact, the history shows that soreness and swelling at the site of injection have normally been recorded as adverse events, while some patients accept moderate nodules within 48 hours with a probability of around 19.6%. Nanomulsion delivery is now employed to optimize DCA release kinetics, thus minimizing inflammatory response effects by 52%.Indeed, this was published in a clinical trial, conducted at Yonsei University, South Korea in 2023, in which compared with 200 patients the local discomfort score for the new version of LIPO VELA V was less than in the conventional DCA regimen by 1.4 points from 5.2 to 3.8 within the VAS pain score. However, if safety is improved, will there be a compromise in efficacy?
That same study in 2023 not only reported that permeability of DCA was enhanced, thus increasing by 36% the rate at which fatty cells die. We are talking really about a nice study, in which a Tokyo medical cosmetics center took in 112 of LIPO VELA V’s new version customers, who, within 14 days of treatment, underwent 3.1mm in reduction of fat layer thickness, with the older version inducing this result only within 21 days. Let’s turn to further very important comparative data: the data we’ve tracked concerning 348 customers in which by week four the uniform reduction in fat gave this new version LIPO VELA V an enhancement of 27% while the rebound rate was reduced down to only 9.2 % (Old version:17.4%): meaning the performance of this new version sets in even faster, yet even more stable whereby the fat layer cannot rebound at such a short time.
Why is such an effect happening?Because we incorporated PDRN, which stimulates skin repair, reduces inflammatory factor IL-6 release, and stabilizes fat metabolism. In 2023, the Seoul University experiment conducted in South Korea showed that including PDRN in the lipolysis solution would 22% drop the inflammatory response during fat metabolism and help accelerate tissue repair-another reason for the rapid recovery of the new version of LIPO VELA V postoperatively. So, the LIPO VELA V is now much safer than before and effective. It also decreases pain during the treatment, enhances fat metabolism, and reduces rebound-you cannot wish for further technical advancement for both doctors and clients.
Who benefits the most?
After receiving the upgrade, the question most frequently asked by physicians is: Who is LIPO VELA V good for? Anyone? In fact, there is a long list of applications for the new version, while some beneficial effects are far more apparent for specific populations.
The stability of the effect is more relevant to customers with a higher BMI. The issue with more than 30 BMI clients is conventional DCA lipolysis tends to slow down fat metabolism; however, the actual reduction in fat, on average over 28 days, was about 2.1 mm.
Nanoemulsification technology helped increase DCA penetration by 53% in the new version LIPO VELA V and thereby enhance fat reduction rates in high-BMI subjects by 41%. Our data collected from a network of medical beauty institutions in New York evidence that customers with BMI 30-35 dropped 4.3mm in fat over a period of 6 weeks after utilizing the new version of LIPO VELA V, which is an advantage of 1.5mm versus the mainstream DCA solution available on the market. The second point is that local body shaping gives the maximum benefit to these customers. Lipolysis injections are for refining body shaping, for example, waist and stomach lines, butterfly sleeves, and outer sides of calf muscles. Yet, small areas are slow in terms of metabolic processing, especially with subcutaneous fat thickness measuring less than 10 mm, with the use of the old version LIPO VELA V; metabolic processing is anywhere from 28% slower when comparing this to large fat sites.
In the latest version, the PPC:DCA ratio was optimized. Hence, customers with fat layer thicknesses below 8mm can improve the fat dissolution metabolism rate by 32% which means the local body shaping effect is more point-specific. In 2023, 32 customers were compared in an experiment conducted in a high-end medical beauty institution in Central Hong Kong. After treating arms, abdomen, calves among other areas with new LIPO VELA V, 25% more uniform fat reduction and 1.7 days of faster recovery post operation was noted. Feedback from the doctors has been that the new version gives much more controllable results, there are almost no hard knots left after injection, and the ease of adjustment of the shaping line has improved by 40%.
Third, for customers who have gone through liposuction surgery, LIPO VELA V can significantly improve the uneven contour after surgery. We tracked 58 customers who had undergone liposuction surgery in the past two years. In 4 weeks after the operation, there was a notable improvement in unevenness in 72% of the customers after using the new version of LIPO VELA V. Only 43% customers who used the traditional DCA lipolysis needle showed a marked effect.
The feedback by the doctor is that the new version has better diffusion, which can act evenly on the fat layer and result in more natural repair effects. From an ROI point of view, the repurchase rate of the new version of LIPO VELA V is up 28%, and especially the repurchase rate of local body shaping people has increased from 41% to 58%
